MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering Post date November 5, 2025 ← MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab → MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day
